March 27, 2020 / 1:07 AM / 10 days ago

BRIEF-Shanghai Junshi Biosciences Says Toripalimab In Combination With Axitinib Granted Orphan-Drug Designation By US FDA

March 27 (Reuters) - Shanghai Junshi Biosciences Co Ltd :

* SHANGHAI JUNSHI BIOSCIENCES - TORIPALIMAB IN COMBINATION WITH AXITINIB FOR TREATMENT OF MUCOSAL MELANOMA GRANTED ORPHAN-DRUG DESIGNATION BY US FDA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below